<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242931</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000447211</org_study_id>
    <secondary_id>OHSU-SOL-04109-L</secondary_id>
    <secondary_id>OHSU-373</secondary_id>
    <nct_id>NCT00242931</nct_id>
  </id_info>
  <brief_title>Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy</brief_title>
  <official_title>Pilot Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy&#xD;
      before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the&#xD;
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may&#xD;
      replace the patient's immune system and help destroy any remaining cancer cells&#xD;
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an&#xD;
      immune response against the body's normal cells. Giving cyclosporine and mycophenolate&#xD;
      mofetil after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fludarabine together with total-body&#xD;
      irradiation works in treating patients who are undergoing a donor stem cell transplant for&#xD;
      progressive metastatic prostate cancer that has not responded to previous hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the treatment-related mortality in patients with hormone-refractory,&#xD;
           progressive metastatic prostate cancer treated with nonmyeloablative conditioning&#xD;
           comprising fludarabine and total-body irradiation followed by allogeneic hematopoietic&#xD;
           stem cell transplantation.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine IV on days -4 to -2&#xD;
           and total-body irradiation (TBI) on day 0.&#xD;
&#xD;
        -  Allogeneic hematopoietic stem cell transplantation (AHSCT): After TBI, patients undergo&#xD;
           AHSCT on day 0.&#xD;
&#xD;
        -  Immunosuppression: Patients receive oral cyclosporine twice daily on days -3 to 56&#xD;
           followed by a taper until day 81. Patients also receive oral mycophenolate mofetil twice&#xD;
           daily on days 0-27 (if patient has a related donor) OR three times daily on days 0-29&#xD;
           and then twice daily on days 30-149 followed by additional tapering until day 180 (if&#xD;
           patient has an unrelated donor).&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to successfully recruit subjects to this study.&#xD;
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality as measured by Kaplan-Meier at 5 years following transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by CTCAE v 3.0 at 100 days following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by RECIST criteria at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression by Kaplan-Meier at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival by Kaplan-Meier at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as measured by a 50% reduction in the prostate-specific antigen at 5 years following transplant</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Fludarabine, TBI, Cyclosporine, MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop&#xD;
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nonmyeloablative stem cell conditioning regimen</intervention_name>
    <description>Conditioning:&#xD;
Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0&#xD;
Hematopoeitic Stem Cell Transplantation:&#xD;
Infusion of peripheral blood stem cells, day 0&#xD;
Immunosuppression:&#xD;
For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop&#xD;
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.</description>
    <arm_group_label>Fludarabine, TBI, Cyclosporine, MMF</arm_group_label>
    <other_name>Mini Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic and progressive disease&#xD;
&#xD;
               -  Refractory to hormonal therapy&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) &gt; 5 ng/mL&#xD;
&#xD;
          -  Previously treated with a docetaxel-based regimen&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 4 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF &gt; 35%&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO &gt; 40% of predicted OR&#xD;
&#xD;
          -  Total lung capacity or FEV_1 &gt; 30% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PATIENT AND DONOR SELECTION CRITERIA&#xD;
&#xD;
        4.1 Patient Inclusion Criteria:&#xD;
&#xD;
        4.1.1 Males aged 18-75.&#xD;
&#xD;
        4.1.2 Pathologically proven adenocarcinoma of the prostate with metastases and progressive&#xD;
        disease (new metastatic lesions or increase in cancer-related pain or a rising PSA defined&#xD;
        by consensus criteria. (A rising PSA will be defined as 2 measurements higher than an&#xD;
        initial value. The second of the 3 measurements must be at least 7 days after the first).&#xD;
&#xD;
        4.1.3 Progressive disease despite hormonal management (including antiandrogen withdrawal, 6&#xD;
        weeks for bicalutamide, 4 weeks for flutamide or nilutamide)&#xD;
&#xD;
        4.1.4 PSA &gt; 5 ng/mL&#xD;
&#xD;
        4.1.5 Serum testosterone level &lt; 50 ng/mL&#xD;
&#xD;
        4.1.6 Prior treatment with a docetaxel-based regimen.&#xD;
&#xD;
        4.1.7 Performance status: Karnofsky Performance Scale (KPS) 70-100%. (Appendix III).&#xD;
&#xD;
        4.1.8 Signed informed patient consent.&#xD;
&#xD;
        4.2 Patient Exclusion criteria:&#xD;
&#xD;
        4.2.1 Expected survival less than 6 months&#xD;
&#xD;
        4.2.2 Active central nervous system involvement or spinal instability&#xD;
&#xD;
        4.2.3 Organ dysfunction:&#xD;
&#xD;
        4.2.3.1 Cardiac: Ejection fraction &lt;35% or symptomatic congestive heart failure.&#xD;
&#xD;
        4.2.3.2 Pulmonary: DLCO &lt;40% of predicted or either TLC or FEV1 &lt; 30% predicted.&#xD;
&#xD;
        4.2.3.3 Liver dysfunction: serum total bilirubin &gt;2x upper limit of normal (ULN) or either&#xD;
        ALT or AST &gt;4x ULN&#xD;
&#xD;
        4.2.3.4 Renal dysfunction: creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
        4.2.4 HIV seropositivity&#xD;
&#xD;
        4.2 Related Donor Inclusion criteria:&#xD;
&#xD;
        4.3.1 Age 18-75&#xD;
&#xD;
        4.3.2 Related to the patient and genotypically or phenotypically HLA-identical. (Appendix&#xD;
        IV)&#xD;
&#xD;
        4.3.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and&#xD;
        apheresis collection. Bone marrow donors are not eligible.&#xD;
&#xD;
        4.3 Unrelated Donor Inclusion criteria:&#xD;
&#xD;
        4.4.1 Age 18-75.&#xD;
&#xD;
        4.4.2 Unrelated donors who are prospectively:&#xD;
&#xD;
        4.4.2.1 Matched for HLA-DRB1 and -DQB1 alleles by high resolution typing AND 4.4.2.2&#xD;
        Matched for all serologically recognized HLA-A or -B or -C antigens and at least five of&#xD;
        six HLA-A or -B or -C alleles as defined by Appendix IV.&#xD;
&#xD;
        4.4.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and&#xD;
        apheresis collection. Bone marrow unrelated donors are not eligible.&#xD;
&#xD;
        4.4 Related and Unrelated Donor Exclusion criteria:&#xD;
&#xD;
        4.5.1 Identical twin.&#xD;
&#xD;
        4.5.2 Any contraindication to the administration of G-CSF for mobilization.&#xD;
&#xD;
        4.5.3 Serious medical or psychological illness.&#xD;
&#xD;
        4.5.4 Prior malignancy within the preceding five years, with the exception of non-melanoma&#xD;
        skin cancers.&#xD;
&#xD;
        4.5.5 HIV seropositivity.&#xD;
&#xD;
        4.5.6 The donor is pregnant, has a positive serum ÃŸhCG or is lactating.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon M. Hayes-Lattin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

